Published in Immunology on March 25, 2011
Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol (2002) 14.75
IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature (2001) 11.03
Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer (2005) 9.46
The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature (2005) 7.18
Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature (2002) 7.07
Roles of the NKG2D immunoreceptor and its ligands. Nat Rev Immunol (2003) 6.95
Ligands for the murine NKG2D receptor: expression by tumor cells and activation of NK cells and macrophages. Nat Immunol (2000) 5.45
NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy. Immunity (2008) 5.35
Antibodies against MICA antigens and kidney-transplant rejection. N Engl J Med (2007) 5.31
Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature (2001) 4.93
Natural killer cells, viruses and cancer. Nat Rev Immunol (2001) 4.21
Retinoic acid early inducible genes define a ligand family for the activating NKG2D receptor in mice. Immunity (2000) 3.84
Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo. Proc Natl Acad Sci U S A (2001) 3.21
A fresh look at tumor immunosurveillance and immunotherapy. Nat Immunol (2001) 2.87
Genome-wide association study in alopecia areata implicates both innate and adaptive immunity. Nature (2010) 2.85
NKG2D blockade prevents autoimmune diabetes in NOD mice. Immunity (2004) 2.80
Stimulation of T cell autoreactivity by anomalous expression of NKG2D and its MIC ligands in rheumatoid arthritis. Proc Natl Acad Sci U S A (2003) 2.64
NKG2D function protects the host from tumor initiation. J Exp Med (2005) 2.19
Cancer immunosurveillance, immunoediting and inflammation: independent or interdependent processes? Curr Opin Immunol (2007) 2.05
The molecular and functional characterization of a dominant minor H antigen, H60. J Immunol (1998) 1.97
Therapy-induced antibodies to MHC class I chain-related protein A antagonize immune suppression and stimulate antitumor cytotoxicity. Proc Natl Acad Sci U S A (2006) 1.88
MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma. Proc Natl Acad Sci U S A (2008) 1.59
Immunodominance of H60 is caused by an abnormally high precursor T cell pool directed against its unique minor histocompatibility antigen peptide. Immunity (2002) 1.47
Comparative analysis of regulatory and effector T cells in progressively growing versus rejecting tumors of similar origins. Cancer Res (2006) 1.39
Engagement of NKG2D by cognate ligand or antibody alone is insufficient to mediate costimulation of human and mouse CD8+ T cells. J Immunol (2005) 1.34
IFN-dependent down-regulation of the NKG2D ligand H60 on tumors. J Immunol (2006) 1.31
Two novel NKG2D ligands of the mouse H60 family with differential expression patterns and binding affinities to NKG2D. J Immunol (2008) 1.31
Cutting edge: down-regulation of MHC class I-related chain A on tumor cells by IFN-gamma-induced microRNA. J Immunol (2009) 1.30
Quantitative analysis of the immune response to mouse non-MHC transplantation antigens in vivo: the H60 histocompatibility antigen dominates over all others. J Immunol (2001) 1.25
Real-time T-cell profiling identifies H60 as a major minor histocompatibility antigen in murine graft-versus-host disease. Blood (2002) 1.23
The relationship of anti-MICA antibodies and MICA expression with heart allograft rejection. Am J Transplant (2007) 1.19
Identification of MICA as a new polymorphic alloantigen recognized by antibodies in sera of organ transplant recipients. Hum Immunol (2000) 1.18
Murine NKG2D ligands: "double, double toil and trouble". Mol Immunol (2008) 0.96
Polymorphisms of MICA recognized by human alloantibodies. Immunogenetics (2008) 0.91
Cutting edge: the minor histocompatibility antigen H60 peptide interacts with both H-2Kb and NKG2D. J Immunol (2002) 0.89
The role of major histocompatibility complex class I chain-related gene A antibodies in organ transplantation. Curr Opin Organ Transplant (2009) 0.87
Role of MICA in the immune response to transplants. Tissue Antigens (2010) 0.86
Now you see it, now you don't! Nat Immunol (2000) 0.85
Studies of the H60a locus in C57BL/6 and 129/Sv mouse strains identify the H60a 3'UTR as a regulator of H60a expression. Mol Immunol (2010) 0.83
A critical function for type I interferons in cancer immunoediting. Nat Immunol (2005) 4.14
Cancer immunoediting by the innate immune system in the absence of adaptive immunity. J Exp Med (2012) 1.93
ERK1/2 regulation of CD44 modulates oral cancer aggressiveness. Cancer Res (2011) 1.34
Cutting edge: down-regulation of MHC class I-related chain A on tumor cells by IFN-gamma-induced microRNA. J Immunol (2009) 1.30
Prolongation of cardiac and islet allograft survival by a blocking hamster anti-mouse CXCR3 monoclonal antibody. Transplantation (2008) 1.22
The host defense peptide cathelicidin is required for NK cell-mediated suppression of tumor growth. J Immunol (2009) 1.04
Modulation of natural killer cell antitumor activity by the aryl hydrocarbon receptor. Proc Natl Acad Sci U S A (2013) 0.99
Strain-specific variation in murine natural killer gene complex contributes to differences in immunosurveillance for urethane-induced lung cancer. Cancer Res (2012) 0.92
Inverse hormesis of cancer growth mediated by narrow ranges of tumor-directed antibodies. Proc Natl Acad Sci U S A (2014) 0.91
Cancer immunoediting of the NK group 2D ligand H60a. J Immunol (2011) 0.89
The clinical implications of antitumor immunity in head and neck cancer. Laryngoscope (2012) 0.89
Cancer immunosurveillance and immunoediting by natural killer cells. Cancer J (2013) 0.86
Studies of the H60a locus in C57BL/6 and 129/Sv mouse strains identify the H60a 3'UTR as a regulator of H60a expression. Mol Immunol (2010) 0.83
Active Ca2+/calmodulin-dependent protein kinase II gamma B impairs positive selection of T cells by modulating TCR signaling. J Immunol (2005) 0.81
A dual function of NKG2D ligands in NK-cell activation. Eur J Immunol (2012) 0.78
Effective long-term immunosuppression in rats by subcutaneously implanted sustained-release tacrolimus pellet: effect on spinally grafted human neural precursor survival. Exp Neurol (2013) 0.76
The nuclear factor-κB pathway down-regulates expression of the NKG2D ligand H60a in vitro: implications for use of nuclear factor-κB inhibitors in cancer therapy. Immunology (2013) 0.75